Antidepressant Long-Term Efficacy Pre-Approval Would Delay New Therapies
Executive Summary
FDA's Psychopharmacologic Drugs Advisory Committee on Oct. 25 agreed with industry's key argument that the proposed requirement to complete long-term efficacy studies at the time of approval for major depressive disorder drugs would delay the entry of new therapies to market